The concern of generic competition has consistently loomed above copyright’s famous drug, PDE5 Inhibitor, raising questions about the outlook of connected drug ventures. While initial years saw significant gains, the patent expiration has allowed the path for cheaper alternatives, potentially reducing profitability and creating a real risk for sh